A Phase 1 Study of ADI-001 in Rheumatoid Arthritis

This is an early-phase study testing ADI-001 — a type of engineered immune cell therapy using gamma delta T cells — as a potential treatment for rheumatoid arthritis (RA), an autoimmune condition that causes painful, swollen joints. This is the first time ADI-001 is being tested in people with RA. **You may be eligible if...** - You are 18 or older - You have been diagnosed with rheumatoid arthritis based on established international criteria - Your liver, heart, blood, and lung function are adequate - You are willing not to take traditional medicines or unprescribed medications during the study - You agree to participate in an extended long-term safety follow-up **You may NOT be eligible if...** - You have severe liver disease (Child-Pugh class B or C) - You need high-dose corticosteroids (prednisone >0.5 mg/kg/day) to control your autoimmune condition - You have had a significant infection (including sepsis, pneumonia, or fungal infection) in the past 4 weeks - You are unwilling to complete the long-term follow-up monitoring period Talk to your doctor to see if this trial is right for you.